Maravai LifeSciences (NASDAQ:MRVI) Hits New 1-Year Low – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $1.95 and last traded at $2.00, with a volume of 127136 shares changing hands. The stock had previously closed at $2.10.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. UBS Group decreased their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research note on Friday, March 21st. Bank of America lowered their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Robert W. Baird downgraded shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. Finally, Baird R W cut Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.31.

Maravai LifeSciences Stock Down 7.6 %

The company has a 50-day moving average of $3.41 and a two-hundred day moving average of $5.35. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a market capitalization of $493.41 million, a PE ratio of -1.18 and a beta of 0.18.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares of the company’s stock, valued at $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.63% of the stock is currently owned by corporate insiders.

Institutional Trading of Maravai LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of the company. Performa Ltd US LLC increased its stake in Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after buying an additional 4,300 shares in the last quarter. FNY Investment Advisers LLC grew its position in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after purchasing an additional 9,916 shares in the last quarter. Cibc World Markets Corp bought a new position in Maravai LifeSciences in the 4th quarter worth approximately $56,000. Finally, Atria Investments Inc purchased a new stake in Maravai LifeSciences during the 4th quarter valued at approximately $58,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.